Provectus Pharmaceuticals to Report Final Efficacy Data on Melanoma at ESMO 2012

Provectus Pharmaceuticals to Report Final Efficacy Data on Melanoma at ESMO 2012

KNOXVILLE, Tenn.--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that final efficacy data from its Phase 2 trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival "PFS" and overall survival), at the ESMO 2012 (European Society for Medical Oncology) Congress in Vienna, Austria on October 1, 2012. These data serve as the basis for planned Phase 3 testing of PV-10 in Stage III melanoma patients with recurrent, in-transit or satellite metastases. A randomized controlled trial to assess PFS against standard care is expected to commence in late 2012 or early 2013 at centers in the USA, Australia and the EU.

Intralesional rose bengal (PV-10) is being investigated for treatment of solid tumors, where it may elicit selective chemoablation of injected lesions and a tumor-specific, immune-mediated bystander response in untreated bystander lesions (i.e., immuno-chemoablation).

The data are included in Abstract #1137P, "Immuno-chemoablation of metastatic melanoma with intralesional rose bengal," and will be presented by Dr. Sanjiv Agarwala, M.D., Principal Investigator for the PV-10 Phase 2 trial, and Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA. The poster is authored by Dr. Agarwala along with co-authors J.F. Thompson, B.M. Smithers, M. Ross, B.J. Coventry, D.R. Minor, C.R. Scoggins and E. Wachter. It will be presented during Poster Presentation III, in Hall XL, from 1:00 p.m. - 2:00 p.m. local time. The abstract can be accessed at the following link:

http://abstracts.webges.com/myitinerary/session-298.html?congress=esmo2012#

Dr. Craig Dees, PhD, CEO of Provectus said, "We are looking forward to Dr. Agarwala's presentation at ESMO, and are particularly encouraged about PV-10's favorable safety and efficacy profile compared with available options for patients suffering from metastatic melanoma. We are also pleased to have this data presented to a prestigious global audience of medical oncologists, as we continue in our path towards regulatory approval of PV-10."

About ESMO

The European Society for Medical Oncology (ESMO) is the leading European professional organization, committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care. Since its founding in 1975 as a non-profit organization, ESMO's mission has been to advance cancer care and cure. It achieves this through fostering and disseminating good science that leads to better medicine and determines best practice. In this way ESMO fulfills its goal to support oncology professionals in providing people with cancer the most effective treatments available and the high-quality care they deserve.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
CFO, COO
or
Porter, LeVay & Rose, Inc.
Investor Relations:
Marlon Nurse, 212-564-4700
DM, SVP
or
Media Relations:
Bill Gordon, 212-564-4700
SVP

KEYWORDS: Austria United States Europe North America Tennessee

INDUSTRY KEYWORDS:

The article Provectus Pharmaceuticals to Report Final Efficacy Data on Melanoma at ESMO 2012 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.